What is Anokion?
Anokion US, Inc. is dedicated to advancing the treatment and prognosis of autoimmune diseases. The company leverages a proprietary antigen-specific immune tolerance technology designed to surpass conventional standards of care by offering enhanced effectiveness and specificity. This innovative approach aims to reduce the immunogenicity of therapeutic proteins and combat autoimmune and allergic conditions. Anokion's platform technology is adaptable to various proteins and clinical applications, positioning it as a key player in the development of next-generation therapies for immune-mediated disorders.
How much funding has Anokion raised?
Anokion has raised a total of $75M across 2 funding rounds:
Series A
$40M
Private Equity
$35M
Series A (2019): $40M, investors not publicly disclosed
Private Equity (2022): $35M led by Pfizer Breakthrough Growth Initiative
Key Investors in Anokion
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative is likely a venture arm of Pfizer, focusing on investing in and accelerating the development of innovative healthcare technologies and companies.
What's next for Anokion?
With a substantial enterprise-level funding context and a recent strategic investment, Anokion is poised for significant growth and advancement in its clinical pipeline. The company's focus on antigen-specific immune tolerance suggests a strategic direction towards developing highly targeted therapies that could redefine the treatment landscape for autoimmune diseases. Future developments will likely involve further clinical trials and potential partnerships to bring its innovative technologies to patients.
See full Anokion company page
